Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluconazole

FDA-approved product (tablet, oral), marketed as Diflucan, Diflucan In Dextrose 5% In Plastic Container, Diflucan In Sodium Chloride 0.9% and 5 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fluconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidiasis
  • Cryptococcal meningitis
  • Urinary tract infection
  • Vulvovaginal candidiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Imidazole and triazole derivatives; Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AC15; WHO ATC J02AC01; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study

    NCT05434104 · start 2026-04-16

    Registered record
    Registry ID
    NCT05434104
    Conditions
    Bacterial Vaginosis; Candida Vaginal
    Interventions
    Vaginal lactoferrin; Usual care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-04-16
    Completion
    2027-12
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Vaginosis; Candida Vaginal
    InterventionVaginal lactoferrin; Usual care
    PhaseNot applicable
    Registry statusRecruiting

  • Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

    NCT07396480 · start 2026-03-01

    Registered record
    Registry ID
    NCT07396480
    Conditions
    Venentoclax; Myeloid Malignancies; Conditioning; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; Acute Myeloid Leucemia; Myeldysplastic Syndrome (MDS)
    Interventions
    Venetoclax in combination with fludarabine and melphalan; Fludarabine and Melphalan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-03-01
    Completion
    2030-06-30
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenentoclax; Myeloid Malignancies; Conditioning; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION +2 more
    InterventionVenetoclax in combination with fludarabine and melphalan; Fludarabine and Melphalan
    PhasePhase 3
    Registry statusRecruiting

  • Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis

    NCT07342153 · start 2025-11-01

    Registered record
    Registry ID
    NCT07342153
    Conditions
    Tinea Corporis; Dermatophytosis
    Interventions
    Itraconazole (200 mg); Fluconazole 150 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-11-01
    Completion
    2026-03-10
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinea Corporis; Dermatophytosis
    InterventionItraconazole (200 mg); Fluconazole 150 mg
    PhasePhase 4
    Registry statusRecruiting

  • Rezafungin Prophylaxis in Liver Transplant

    NCT06774144 · start 2025-10-15

    Registered record
    Registry ID
    NCT06774144
    Conditions
    Liver Transplant Infection; Fungal Infection
    Interventions
    Rezafungin; Standard of care antifungal prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2025-10-15
    Completion
    2028-12
    Enrolment
    385

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant Infection; Fungal Infection
    InterventionRezafungin; Standard of care antifungal prophylaxis
    PhasePhase 3
    Registry statusEnrolling by invitation

  • Fractional CO₂ Laser or 40% Urea With Topical Fluconazole Microemulsion in Onychomycosis

    NCT07033962 · start 2025-06

    Registered record
    Registry ID
    NCT07033962
    Conditions
    Onychomycosis
    Interventions
    "Fractional CO2 laser" and "topical fluconazole microemulsion"; "Urea 40%" and "topical fluconazole microemulsion"
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-06
    Completion
    2026-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnychomycosis
    Intervention"Fractional CO2 laser" and "topical fluconazole microemulsion"; "Urea 40%" and "topical fluconazole microemulsion"
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

    NCT06593457 · start 2024-08-20

    Registered record
    Registry ID
    NCT06593457
    Conditions
    Healthy Volunteers
    Interventions
    IP; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-08-20
    Completion
    2024-11-14
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionIP; Matching Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults

    NCT06173596 · start 2024-01-10

    Registered record
    Registry ID
    NCT06173596
    Conditions
    Healthy
    Interventions
    ALXN2080; Itraconazole; Fluconazole (AxMP); Carbamazepine (AxMP)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-01-10
    Completion
    2024-05-16
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionALXN2080; Itraconazole; Fluconazole (AxMP); Carbamazepine (AxMP)
    PhasePhase 1
    Registry statusCompleted

  • Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects

    NCT05661591 · start 2023-02-28

    Registered record
    Registry ID
    NCT05661591
    Conditions
    Malignant Tumor
    Interventions
    SHR2554 Tablets; Fluconazole Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-02-28
    Completion
    2023-03-31
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Tumor
    InterventionSHR2554 Tablets; Fluconazole Capsules
    PhasePhase 1
    Registry statusCompleted

  • Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

    NCT05657613 · start 2023-01-03

    Registered record
    Registry ID
    NCT05657613
    Conditions
    Drug Interactions
    Interventions
    CYP450 Cocktail and Transporter Substrates with Pacritinib; Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib; Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-01-03
    Completion
    2023-06-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interactions
    InterventionCYP450 Cocktail and Transporter Substrates with Pacritinib; Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib; Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of Fluconazole in Children (2-18 Years)

    NCT05130723 · start 2022-10-18

    Registered record
    Registry ID
    NCT05130723
    Conditions
    Invasive Fungal Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-10-18
    Completion
    2023-10-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

    NCT05471063 · start 2022-08-22

    Registered record
    Registry ID
    NCT05471063
    Conditions
    Cryptococcal Meningitis
    Interventions
    Amphotericin B Colloidal Dispersion; flucytosine; fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-08-22
    Completion
    2023-04-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptococcal Meningitis
    InterventionAmphotericin B Colloidal Dispersion; flucytosine; fluconazole
    PhaseNot applicable
    Registry statusUnknown

  • Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

    NCT05478772 · start 2022-07-11

    Registered record
    Registry ID
    NCT05478772
    Conditions
    Health Volunteers
    Interventions
    CTP-543; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-11
    Completion
    2022-08-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealth Volunteers
    InterventionCTP-543; Fluconazole
    PhasePhase 1
    Registry statusCompleted

  • HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

    NCT05602597 · start 2022-06-01

    Registered record
    Registry ID
    NCT05602597
    Conditions
    Relapsed or Refractory Lymphoma
    Interventions
    Itraconazole 200 mg; Fluconazole 400 mg; Rifampin 600 mg; Rabeprazole 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-01
    Completion
    2022-08-06
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Lymphoma
    InterventionItraconazole 200 mg; Fluconazole 400 mg; Rifampin 600 mg; Rabeprazole 40 mg
    PhasePhase 1
    Registry statusCompleted

  • Candida PCR Diagnosis Strategy in Patients From Intensive Care Units

    NCT04874441 · start 2022-05-19

    Registered record
    Registry ID
    NCT04874441
    Conditions
    Candida
    Interventions
    Diagnosis strategy based on C. glabrata / krusei PCR
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-05-19
    Completion
    2025-04-14
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandida
    InterventionDiagnosis strategy based on C. glabrata / krusei PCR
    PhaseNot applicable
    Registry statusCompleted

  • The Effects of Gut Micribiota Disruption on the Immune Response After Open Heart Surgery

    NCT03939273 · start 2022-03

    Registered record
    Registry ID
    NCT03939273
    Conditions
    Systemic Inflammatory Response Syndrome; Postoperative Shock; Coronary Artery Disease; Extracorporeal Circulation; Complications
    Interventions
    Vancomycin Oral; Metronidazole Oral; Ciprofloxacin Pill; Fluconazole Oral Product; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-03
    Completion
    2023-03
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Inflammatory Response Syndrome; Postoperative Shock; Coronary Artery Disease; Extracorporeal Circulation +1 more
    InterventionVancomycin Oral; Metronidazole Oral; Ciprofloxacin Pill; Fluconazole Oral Product +1 more
    PhaseNot applicable
    Registry statusUnknown